Mark Lythgoe, Clinical Research Fellow in Medical Oncology at Imperial College London, shared a post on X:
“Not all PDL1 assays are the same in bladder cancer – important work. do we need to re-evaluate the clinical utility of how we measure PDL1 and does this have implications for other cancers???”
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
Authors: Matthew D. Galsky et al.
